Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab

A 35-year-old man with refractory Crohn's disease showed a loss of response to infliximab after requiring treatment with infliximab at 10 mg/kg together with steroid to maintain remission. His symptoms recurred, and colonoscopy showed extensive active ulcers in the colon. Adrenomedullin therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashizuka, Shinya, Kuroishi, Nobuko, Nakashima, Koji, Inatsu, Haruhiko, Kita, Toshihiro, Kitamura, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599938/
https://www.ncbi.nlm.nih.gov/pubmed/30713309
http://dx.doi.org/10.2169/internalmedicine.1791-18
_version_ 1783431017986523136
author Ashizuka, Shinya
Kuroishi, Nobuko
Nakashima, Koji
Inatsu, Haruhiko
Kita, Toshihiro
Kitamura, Kazuo
author_facet Ashizuka, Shinya
Kuroishi, Nobuko
Nakashima, Koji
Inatsu, Haruhiko
Kita, Toshihiro
Kitamura, Kazuo
author_sort Ashizuka, Shinya
collection PubMed
description A 35-year-old man with refractory Crohn's disease showed a loss of response to infliximab after requiring treatment with infliximab at 10 mg/kg together with steroid to maintain remission. His symptoms recurred, and colonoscopy showed extensive active ulcers in the colon. Adrenomedullin therapy was started in addition to the conventional infliximab therapy. A few days after, his symptoms went into remission. Endoscopy at 2 and 7 weeks revealed significant mucosal remission without steroid therapy. Adrenomedullin promoted mucosal healing and led to the re-induction of remission in Crohn's disease in a patient with a loss of response to infliximab.
format Online
Article
Text
id pubmed-6599938
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-65999382019-07-01 Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab Ashizuka, Shinya Kuroishi, Nobuko Nakashima, Koji Inatsu, Haruhiko Kita, Toshihiro Kitamura, Kazuo Intern Med Case Report A 35-year-old man with refractory Crohn's disease showed a loss of response to infliximab after requiring treatment with infliximab at 10 mg/kg together with steroid to maintain remission. His symptoms recurred, and colonoscopy showed extensive active ulcers in the colon. Adrenomedullin therapy was started in addition to the conventional infliximab therapy. A few days after, his symptoms went into remission. Endoscopy at 2 and 7 weeks revealed significant mucosal remission without steroid therapy. Adrenomedullin promoted mucosal healing and led to the re-induction of remission in Crohn's disease in a patient with a loss of response to infliximab. The Japanese Society of Internal Medicine 2019-02-01 2019-06-01 /pmc/articles/PMC6599938/ /pubmed/30713309 http://dx.doi.org/10.2169/internalmedicine.1791-18 Text en Copyright © 2019 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Ashizuka, Shinya
Kuroishi, Nobuko
Nakashima, Koji
Inatsu, Haruhiko
Kita, Toshihiro
Kitamura, Kazuo
Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab
title Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab
title_full Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab
title_fullStr Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab
title_full_unstemmed Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab
title_short Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab
title_sort adrenomedullin: a novel therapy for intractable crohn's disease with a loss of response to infliximab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599938/
https://www.ncbi.nlm.nih.gov/pubmed/30713309
http://dx.doi.org/10.2169/internalmedicine.1791-18
work_keys_str_mv AT ashizukashinya adrenomedullinanoveltherapyforintractablecrohnsdiseasewithalossofresponsetoinfliximab
AT kuroishinobuko adrenomedullinanoveltherapyforintractablecrohnsdiseasewithalossofresponsetoinfliximab
AT nakashimakoji adrenomedullinanoveltherapyforintractablecrohnsdiseasewithalossofresponsetoinfliximab
AT inatsuharuhiko adrenomedullinanoveltherapyforintractablecrohnsdiseasewithalossofresponsetoinfliximab
AT kitatoshihiro adrenomedullinanoveltherapyforintractablecrohnsdiseasewithalossofresponsetoinfliximab
AT kitamurakazuo adrenomedullinanoveltherapyforintractablecrohnsdiseasewithalossofresponsetoinfliximab

Ejemplares similares